Blueprint Medicines Corp (BPMC):企業の財務・戦略的SWOT分析

◆英語タイトル:Blueprint Medicines Corp (BPMC) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH325832FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥84,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥126,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, discovers and develops precision therapies for the treatment of cancers and rare diseases. The company offers AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST); and GAVRETO (pralsetinib) against non-small cell lung cancer (NSCLC) in adults. It is investigating fisogatinib for the treatment of advanced hepatocellular carcinoma; BLU-263 targeting indolent systemic mastocytosis. Blueprint Medicines is also advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors; and avapritinib to treat advanced systemic mastocytosis. The company utilizes its discover engine which combines bioinformatics and drug design capabilities to develop its medicines. Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.

Blueprint Medicines Corp Key Recent Developments

Apr 05,2021: Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021
Mar 10,2021: Blueprint Medicines to showcase scientific leadership in precision oncology and Hhematology at AACR Annual Meeting 2021
Feb 17,2021: Blueprint medicines reports fourth quarter and full year 2020 financial results

This comprehensive SWOT profile of Blueprint Medicines Corp provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Blueprint Medicines Corp including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Blueprint Medicines Corp – Key Information
Blueprint Medicines Corp – Overview
Blueprint Medicines Corp – Key Employees
Blueprint Medicines Corp – Key Employee Biographies
Blueprint Medicines Corp – Key Operational Heads
Blueprint Medicines Corp – Major Products and Services
Blueprint Medicines Corp – History
Blueprint Medicines Corp – Company Statement
Blueprint Medicines Corp – Locations And Subsidiaries
Blueprint Medicines Corp
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Blueprint Medicines Corp – Business Description
Blueprint Medicines Corp – Corporate Strategy
Blueprint Medicines Corp – SWOT Analysis
SWOT Analysis – Overview
Blueprint Medicines Corp – Strengths
Blueprint Medicines Corp – Weaknesses
Blueprint Medicines Corp – Opportunities
Blueprint Medicines Corp – Threats
Blueprint Medicines Corp – Key Competitors

Section 3 – Company Financial Performance Charts

Blueprint Medicines Corp – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Blueprint Medicines Corp, Key Information
Blueprint Medicines Corp, Key Ratios
Blueprint Medicines Corp, Share Data
Blueprint Medicines Corp, Major Products and Services
Blueprint Medicines Corp, History
Blueprint Medicines Corp, Key Employees
Blueprint Medicines Corp, Key Employee Biographies
Blueprint Medicines Corp, Key Operational Heads
Blueprint Medicines Corp, Other Locations
Blueprint Medicines Corp, Subsidiaries
Blueprint Medicines Corp, Key Competitors
Blueprint Medicines Corp, SWOT Analysis
Blueprint Medicines Corp, Ratios based on current share price
Blueprint Medicines Corp, Annual Ratios
Blueprint Medicines Corp, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Blueprint Medicines Corp (BPMC):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Covaris Inc-医療機器分野:企業M&A・提携分析
    Summary Covaris Inc (Covaris) is a technology company that offers pre-analytical tools and devices. The company’s products comprise instruments, kits and reagents and consumables. It offers kits and reagents which include truXTRAC FFPE DNA and RNA Kits; truXTRAC automation, FFPE sample collection, t …
  • Safety-Kleen, Inc.:企業の戦略・SWOT・財務分析
    Safety-Kleen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Safety-Kleen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • TiGenix NV (TIG):企業の財務・戦略的SWOT分析
    Summary TiGenix NV (TiGenix), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and commercializes novel therapeutic products. The company exploits the anti-inflammatory properties of stem cells to develop novel therapies. It offers products such as AlloCSC-0 …
  • VSTECS Holdings Ltd:企業の戦略・SWOT・財務情報
    VSTECS Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary VSTECS Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Uni-Select Inc.:企業のM&A・事業提携・投資動向
    Uni-Select Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Uni-Select Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Xenon Pharmaceuticals Inc (XENE):企業の財務・戦略的SWOT分析
    Summary Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc, is a biopharmaceutical company that develops medicines to treat neurological disorders. The company is investigating XEN1101, a Kv7 potassium channel modulator against epilepsy; XEN496 for the treatment of seizures associated wi …
  • LG Electronics Inc (066570):企業の財務・戦略的SWOT分析
    LG Electronics Inc (066570) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Auris Medical Holding Ltd (EARS):企業の財務・戦略的SWOT分析
    Auris Medical Holding Ltd (EARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Pioneer Hi-Bred International Inc:企業のM&A・事業提携・投資動向
    Pioneer Hi-Bred International Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pioneer Hi-Bred International Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • ChemRar High-Tech Center:製薬・医療:M&Aディール及び事業提携情報
    Summary ChemRar High-Tech Center (CHTC) is a developer of drugs for life-threatening diseases. The company offers drugs for the treatment of cancer, central nervous system, infectious, metabolic and cardiovascular diseases. It also offers pre-clinical and clinical research of new molecules including …
  • Cellmid Ltd (CDY):製薬・医療:M&Aディール及び事業提携情報
    Summary Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd, is a life sciences company that develops and commercializes diagnostic and therapeutic products. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such a …
  • Toyo Tire & Rubber Co Ltd (5105):企業の財務・戦略的SWOT分析
    Toyo Tire & Rubber Co Ltd (5105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Oldenburgische Landesbank AG:企業の戦略・SWOT・財務分析
    Oldenburgische Landesbank AG - Strategy, SWOT and Corporate Finance Report Summary Oldenburgische Landesbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Ceragon Networks Ltd (CRNT):企業の財務・戦略的SWOT分析
    Ceragon Networks Ltd (CRNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • The Macerich Co:企業のM&A・事業提携・投資動向
    The Macerich Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Macerich Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Global Investment House KPSC:企業の戦略的SWOT分析
    Global Investment House KPSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Sarku Japan:企業の戦略・SWOT・財務情報
    Sarku Japan - Strategy, SWOT and Corporate Finance Report Summary Sarku Japan - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Garden Fresh Restaurant Corp:企業の戦略・SWOT・財務情報
    Garden Fresh Restaurant Corp - Strategy, SWOT and Corporate Finance Report Summary Garden Fresh Restaurant Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Investment Technology Group, Inc.:企業の戦略・SWOT・財務情報
    Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Media General, Inc.:企業のM&A・事業提携・投資動向
    Media General, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Media General, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆